Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and-2 trials

被引：0
|
作者：
Bauer, Andrea [1 ]
Schuttelaar, Marie-Louise [2 ]
Baranowski, Keith [3 ]
Plohberger, Ursula [3 ]
Sorensen, Laura [3 ]
Worm, Margitta [4 ]
机构：
[1] Tech Univ Dresden, Univ Allergy Ctr, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[3] LEO Pharm A S, Ballerup, Denmark
[4] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergy, Div Allergy & Immunol, Berlin, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
chronic hand eczema; delgocitinib; JAK;
D O I：
10.1093/bjd/ljae266.033
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
654
引用
收藏
页数：2
相关论文
共 49 条
  • [41] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials
    Barjaktarevic, I.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [42] Severe infections, confirmed extended major adverse cardiovascular events, and malignancies over 5 years of treatment with tildrakizumab in terms of number needed to harm: Pooled analyses from the reSURFACE 1 and reSURFACE 2 phase 3 trials
    Pinter, Andreas
    Lacour, Jean-Philippe
    Egeberg, Alexander
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB108 - AB108
  • [43] Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks
    Paller, Amy S.
    Mendes-Bastos, Pedro
    Eichenfield, Lawrence F.
    Soong, Weily
    Lio, Peter
    Prajapati, Vimal H.
    Platt, Andrew M.
    Raymundo, Eliza
    Liu, John
    Ladizinski, Barry
    Thyssen, Jacob P.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [44] Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks
    Paller, Amy
    Mendes-Bastos, Pedro
    Eichenfield, Lawrence
    Soong, Weily
    Lio, Peter
    Prajapati, Vimal
    Platt, Andrew
    Liu, John
    Ladizinski, Barry
    Thyssen, Jacob
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB157 - AB157
  • [45] Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
    Silverberg, Jonathan, I
    Wollenberg, Andreas
    Reich, Adam
    Thaci, Diamant
    Legat, Franz J.
    Papp, Kim A.
    Gold, Linda Stein
    Bouaziz, Jean-David
    Pink, Andrew E.
    Carrascosa, Jose Manuel
    Rewerska, Barbara
    Szepietowski, Jacek C.
    Krasowska, Dorota
    Havlickova, Blanka
    Kalowska, Monika
    Magnolo, Nina
    Pauser, Sylvia
    Nami, Navid
    Sauder, Maxwell B.
    Jain, Vipul
    Padlewska, Kamila
    Cheong, Soo Yeon
    Morel, Patricia Fleuranceau
    Ulianov, Liliana
    Piketty, Christophe
    LANCET, 2024, 404 (10451): : 445 - 460
  • [46] Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2
    Lio, Peter
    Nosbaum, Audrey
    Cardillo, Tracy
    DeLozier, Amy
    Gamalo, Margaret
    Ball, Susan G.
    Bieber, Thomas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB28 - AB28
  • [47] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
  • [48] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
    Blauvelt, Andrew
    Kircik, Leon
    Schlesinger, Todd
    Pierce, Evangeline
    Burge, Russel
    Behling, Michael
    Atwater, Amber Reck
    Elmaraghy, Hany
    Armstrong, April
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
  • [49] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (MeasureUp 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (vol 397, pg 2151, 2021)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Katoh, Norito
    LANCET, 2021, 397 (10290): : 2150 - 2150
12345